Paclitaxel (PTX) and/or cisplatin (CDDP), as important cytotoxic anti-cancer agents, are widely used to treat various solid tumors. Both may cause moderate or severe neurotoxicity, but ocular neurotoxicity is also occasionally reported. A patient diagnosed with nasopharyngeal cancer suffering acute ocular neurotoxicity 10 days after paclitaxel and CDDP administration at the recommended dose is described in the present case report, and PTX- and/or CDDP-induced ocular neurotoxicity are summarized according to previous reports. Possible mechanisms and the potential diagnostic, therapeutic and predictive strategies of PTX- and/or CDDP-induced ocular neurotoxicity are reviewed, to help the oncologist to take the infrequent toxicity of cytotoxic drugs into account and improve patient safety during anti-cancer therapy. © 2014 Li et al.
CITATION STYLE
Li, Y., Li, Y., Li, J., Pi, G., & Tan, W. (2014). Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: A case report and literature review. OncoTargets and Therapy, 7, 1361–1366. https://doi.org/10.2147/OTT.S65774
Mendeley helps you to discover research relevant for your work.